Rimegepant

Rimegepant
Clinical data
Trade names	Nurtec ODT
Other names	BHV-3000, BMS-927711
AHFS/Drugs.com	Monograph
MedlinePlus	a620031
License data	US DailyMed: Rimegepant;
Routes of; administration	By mouth
Drug class	calcitonin gene-related peptide receptor antagonist
ATC code	none;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate;
CAS Number	1289023-67-1;
PubChem CID	51049968;
DrugBank	DB12457;
ChemSpider	27289072;
UNII	997WVV895X;
KEGG	D10663; D10662;
ChEMBL	ChEMBL2178422;
CompTox Dashboard (EPA)	DTXSID70156003 ;
Chemical and physical data
Formula	C28H28F2N6O3
Molar mass	534.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;
	InChI InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1; Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N;

Rimegepant, sold under the brand name Nurtec ODT, is a medication for the treatment of an acute migraine with or without aura in adults.[1] It is not used prophylactically.[2]

Taken by mouth to dissolve on or under the tongue,[2] rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It is not a narcotic and has no addictive potential; thus it is not designated as a controlled substance. It works by blocking CGRP receptors.

Approved for use in the United States in February 2020, rimegepant is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.[3][1]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[4]

History

Originally discovered at Bristol-Myers Squibb,[5] rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020.[6] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.[1]

References

"Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Retrieved 19 March 2020. This article incorporates text from this source, which is in the public domain.
"Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Retrieved 19 March 2020.
"Nurtec ODT: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.
Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.
"Rimegepant - Biohaven Pharmaceuticals Holding Company". Adis Insight. Springer Nature Switzerland AG.
"Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020 – via PR Newswire.

External links

"Rimegepant". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT03461757 for "Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[FDA_snapshot-1] "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Retrieved 19 March 2020. This article incorporates text from this source, which is in the public domain.

[Nurtec_ODT_FDA_label-2] "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Retrieved 19 March 2020.

[3] "Nurtec ODT: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.

[4] Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.

[5] "Rimegepant - Biohaven Pharmaceuticals Holding Company". Adis Insight. Springer Nature Switzerland AG.

[6] "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020 – via PR Newswire.